|
1
|
Keating GM: Rituximab: A review of its use
in chronic lymphocytic leukaemia, low-grade or follicular lymphoma
and diffuse large B-cell lymphoma. Drugs. 70:1445–1476. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mendes D, Alves C, Afonso N, Cardoso F,
Passos-Coelho JL, Costa L, Andrade S and Batel-Marques F: The
benefit of HER2-targeted therapies on overall survival of patients
with metastatic HER2-positive breast cancer-a systematic review.
Breast Cancer Res. 17:1402015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin P, Furman RR, Coleman M and Leonard
JP: Phase I to III trials of anti-B cell therapy in non-Hodgkin's
lymphoma. Clin Cancer Res. 13:5636s–5642s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salles G, Seymour JF, Offner F,
López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R,
Catalano JV, Brice P, et al: Rituximab maintenance for 2 years in
patients with high tumour burden follicular lymphoma responding to
rituximab plus chemotherapy (PRIMA): A phase 3, randomised
controlled trial. Lancet. 377:42–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tam CS, O'Brien S, Plunkett W, Wierda W,
Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, et
al: Long-term results of first salvage treatment in CLL patients
treated initially with FCR (fludarabine, cyclophosphamide,
rituximab). Blood. 124:3059–3064. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bowles JA, Wang SY, Link BK, Allan B,
Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith
BJ, et al: Anti-CD20 monoclonal antibody with enhanced affinity for
CD16 activates NK cells at lower concentrations and more
effectively than rituximab. Blood. 108:2648–2654. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Di Gaetano N, Cittera E, Nota R, Vecchi A,
Grieco V, Scanziani E, Botto M, Introna M and Golay J: Complement
activation determines the therapeutic activity of rituximab in
vivo. J Immunol. 171:1581–1587. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Byrd JC, Kitada S, Flinn IW, Aron JL,
Pearson M, Lucas D and Reed JC: The mechanism of tumor cell
clearance by rituximab in vivo in patients with B-cell chronic
lymphocytic leukemia: Evidence of caspase activation and apoptosis
induction. Blood. 99:1038–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weiner GJ: Rituximab: Mechanism of action.
Semin Hematol. 47:115–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cartron G, Dacheux L, Salles G,
Solal-Celigny P, Bardos P, Colombat P and Watier H: Therapeutic
activity of humanized anti-CD20 monoclonal antibody and
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood.
99:754–758. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ,
Hwang SH, Yun S, Joo J and Kim HJ: Treatment outcomes with
rituximab in 100 patients with neuromyelitis optica: Influence of
FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA
Neurol. 72:989–995. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gennari R, Menard S, Fagnoni F, Ponchio L,
Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C,
Gibelli N, et al: Pilot study of the mechanism of action of
preoperative trastuzumab in patients with primary operable breast
tumors overexpressing HER2. Clin Cancer Res. 10:5650–5655. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Gordon M, Schultheis AM, Yang DY,
Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, et
al: FCGR2A and FCGR3A polymorphisms associated with clinical
outcome of epidermal growth factor receptor expressing metastatic
colorectal cancer patients treated with single-agent cetuximab. J
Clin Oncol. 25:3712–3718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ravetch JV and Perussia B: Alternative
membrane forms of Fc gamma RIII(CD16) on human natural killer cells
and neutrophils. Cell type-specific expression of two genes that
differ in single nucleotide substations. J Exp Med. 170:481–497.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vaknin-Dembinsky A, Charbit H, Brill L,
Abramsky O, Gur-Wahnon D, Ben-Dov IZ and Lavon I: Circulating
microRNAs as biomarkers for rituximab therapy, in neuromyelitis
optica (NMO). J Neuroinflammation. 13:1792016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dall'Ozzo S, Tartas S, Paintaud G, Cartron
G, Colombat P, Bardos P, Watier H and Thibault G:
Rituximab-dependent cytotoxicity by natural killer cells: Influence
of FCGR3A polymorphism on the concentration-effect relationship.
Cancer Res. 64:4664–4669. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
López-Albaitero A, Lee SC, Morgan S,
Grandis JR, Gooding WE, Ferrone S and Ferris RL: Role of
polymorphic Fc gamma receptor IIIa and EGFR expression level in
cetuximab mediated, NK cell dependent in vitro cytotoxicity of head
and neck squamous cell carcinoma cells. Cancer Immunol Immunother.
58:1853–1864. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Preithner S, Elm S, Lippold S, Locher M,
Wolf A, da Silva AJ, Baeuerle PA and Prang NS: High concentrations
of therapeutic IgG1 antibodies are needed to compensate for
inhibition of antibody-dependent cellular cytotoxicity by excess
endogenous immunoglobulin G. Mol Immunol. 43:1183–1193. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rimawi MF, Schiff R and Osborne CK:
Targeting HER2 for the treatment of breast cancer. Annu Rev Med.
66:111–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Klepfish A, Rachmilewitz EA, Kotsianidis
I, Patchenko P and Schattner A: Adding fresh frozen plasma to
rituximab for the treatment of patients with refractory advanced
CLL. QJM. 101:737–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abraham K, Lugassy G, Kotsianidis I,
Rachmilewitz EA and Schattner A: Enhancing the action of rituximab
in chronic lymphocytic leukemia by adding fresh frozen plasma:
Complement/rituximab interactions & clinical results in
refractory CLL. Ann N Y Acad Sci. 1173:865–873. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
An N, Ou-Yang XY, Cao CF, Ye J and Hui RT:
Association of Fc gamma receptors IIIA gene polymorphisms with the
susceptibility to periodontitis in Chinese patients. Beijing Da Xue
Xue Bao Yi Xue Ban. 41:40–43. 2009.(In Chinese). PubMed/NCBI
|
|
23
|
Bigley AB, Spielmann G, Agha N and Simpson
RJ: The effects of age and latent cytomegalovirus infection on
NK-cell phenotype and exercise responsiveness in man. Oxid Med Cell
Longev. 2015:9796452015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Son BK, Roberts RL, Ank BJ and Stiehm ER:
Effects of anticoagulant, serum, and temperature on the natural
killer activity of human peripheral blood mononuclear cells stored
overnight. Clin Diagn Lab Immunol. 3:260–264. 1996.PubMed/NCBI
|
|
25
|
Düesberg U, Schneiders AM, Flieger D,
Inchauspé G, Sauerbruch T and Spengler U: Natural cytotoxicity and
antibody-dependent cellular cytotoxicity (ADCC) is not impaired in
patients suffering from chronic hepatitis C. J Hepatol. 35:650–657.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dechant M, Beyer T, Schneider-Merck T,
Weisner W, Peipp M, van de Winkel JG and Valerius T: Effector
mechanisms of recombinant IgA antibodies against epidermal growth
factor receptor. J Immunol. 179:2936–2943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boisson B, Laplantine E, Prando C, Giliani
S, Israelsson E, Xu Z, Abhyankar A, Israël L, Trevejo-Nunez G,
Bogunovic D, et al: Immunodeficiency, autoinflammation and
amylopectinosis in humans with inherited HOIL-1 and LUBAC
deficiency. Nat Immunol. 13:1178–1186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nechansky A, Schuster M, Just W, Siegl P,
Wiederkum S, Gorr G and Kircheis R: Compensation of endogenous IgG
mediated inhibition of antibody-dependent cellular cytotoxicity by
glycol-engineering of therapeutic antibodies. Mol Immunol.
44:1815–1817. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhuang Y, Xu W, Shen Y and Li J: Fcγ
receptor polymorphisms and clinical efficacy of rituximab in
non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin
Lymphoma Myeloma Leuk. 10:347–352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dubaniewicz A, Typiak M, Wybieralska M,
Szadurska M, Nowakowski S, Staniewicz-Panasik A, Rogoza K, Sternau
A, Deeg P and Trzonkowski P: Changed phagocytic activity and
pattern of Fcγ and complement receptors on blood monocytes in
sarcoidosis. Hum Immunol. 73:788–794. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hans VM and Mehta DS: Genetic polymorphism
of Fcγ-receptors IIa, IIIa and IIIb in South Indian patients with
generalized aggressive periodontitis. J Oral Sci. 53:467–474. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perussia B, Trinchieri G, Jackson A,
Warner NL, Faust J, Rumpold H, Kraft D and Lanier LL: The Fc
receptor for IgG on human natural killer cells: Phenotypie,
functional, and comparative studies with monoclonal antibodies. J
Immunol. 133:180–189. 1984.PubMed/NCBI
|
|
33
|
Ghielmini M, Rufibach K, Salles G,
Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M,
Martinelli G, Stahel R, Lohri A, et al: Single agent rituximab in
patients with follicular or mantle cell lymphoma: Clinical and
biological factors that are predictive of response and event-free
survival as well as the effect of rituximab on the immune system: A
study of the Swiss Group for Clinical Cancer Research (SAKK). Ann
Oncol. 16:1675–1682. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Treon SP, Hansen M, Branagan AR, Verselis
S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull
B, Anderson KC, et al: Polymorphisms in FcgammaRIIIA (CD16)
receptor expression are associated with clinical response to
rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol.
23:474–481. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH,
Park YH, Do YR, Shin HJ, Kim MK, Hyun MS and Sohn SK: FcGRIIIa gene
polymorphisms may correlate with response to frontline R-CHOP
therapy for diffuse large B-cell lymphoma. Blood. 108:2720–2725.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hatjiharissi E, Xu L, Santos DD, Hunter
ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu
X, et al: Increased natural killer cell expression of CD16,
augmented binding and ADCC activity to rituximab among individuals
expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood.
110:2561–2564. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tateishi K and Matsushita M: Activation of
the alternative complement pathway by mannose-binding lectin via a
C2-bypass pathway. Microbiol Immunol. 55:817–821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van Meerten T, van Rijn RS, Hol S,
Hagenbeek A and Ebeling SB: Complement-induced cell death by
rituximab depends on CD20 expression level and acts complementary
to antibody-dependent cellular cytotoxicity. Clin Cancer Res.
12:4027–4035. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bellosillo B, Villamor N, López-Guillermo
A, Marcé S, Esteve J, Campo E, Colomer D and Montserrat E:
Complement-mediated cell death induced by rituximab in B-cell
lymphoproliferative disorders is mediated in vitro by a
caspase-independent mechanism involving the generation of reactive
oxygen species. Blood. 98:2771–2777. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Golay J, Lazzari M, Facchinetti V,
Bernasconi S, Borleri G, Barbui T, Rambaldi A and Introna M: CD20
levels determine the in vitro susceptibility to rituximab and
complement of B-cell chronic lymphocytic leukemia: Further
regulation by CD55 and CD59. Blood. 98:3383–3389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shushakova N, Skokowa J, Schulman J,
Baumann U, Zwirner J, Schmidt RE and Gessner JE: C5a anaphylatoxin
is a major regulator of activating versus inhibitory FcgammaRs in
immune complex induced lung disease. J Clin Invest. 110:1823–1830.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schmidt RE and Gessner JE: Fc receptors
and their interaction with complement in autoimmunity. Immunol
Lett. 100:56–67. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huber-Lang M, Sarma JV, Zetoune FS,
Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA,
Hoesel LM, et al: Generation of C5a in the absence of C3: A new
complement activation pathway. Nat Med. 12:682–687. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kumar V, Ali SR, Konrad S, Zwirner J,
Verbeek JS, Schmidt RE and Gessner JE: Cell-derived anaphylatoxins
as key mediators of antibody-dependent type II autoimmunity in
mice. J Clin Invest. 116:512–520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Carlsten M, Levy E, Karambelkar A, Li L,
Reger R, Berg M, Peshwa MV and Childs RW: Efficient mRNA-based
genetic engineering of human NK cells with high-affinity CD16 and
CCR7 augments rituximab-induced ADCC against lymphoma and targets
NK cell migration toward the lymph Node-associated chemokine CCL19.
Front Immunol. 7:1052016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Deo YM, Graziano RF, Repp R and van de
Winkel JG: Clinical significance of IgG Fc receptors and Fc gamma
R-directed immunotherapies. Immunol Today. 18:127–135. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dettke M and Loibner H: Different types of
FCgamma-receptors are involved in anti-Lewis Y antibody induced
effector functions in vitro. Br J Cancer. 82:441–445. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Radaev S, Motyka S, Fridman WH,
Sautes-Fridman C and Sun PD: The structure of a human type III Fc
receptor in complex with Fc. J Biol Chem. 276:16469–16477. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sulica A, Morel P, Metes D and Herberman
RB: Ig-binding receptors on human NK cells as effector and
regulatory surface molecules. Int Rev Immunol. 20:371–414. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang SY, Racila E, Taylor RP and Weiner
GJ: NK-cell activation and antibody-dependent cellular cytotoxicity
induced by rituximab-coated target cells is inhibited by the C3b
component of complement. Blood. 111:1456–1463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nakamaki T, Fukuchi K, Nakashima H,
Ariizumi H, Maeda T, Saito B, Yanagisawa K, Tomoyasu S, Homma M,
Shiozawa E, et al: CD20 gene deletion causes a CD20-negative
relapse in diffuse large B-cell lymphoma. Eur J Haematol.
89:350–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Maeshima AM, Taniguchi H, Fukuhara S,
Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi
Y, Tobinai K and Tsuda H: Follow-up data of 10 patients with B-cell
non-Hodgkin lymphoma with a CD20-negative phenotypic change after
rituximab-containing therapy. Am J Surg Pathol. 37:563–570. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Duman BB, Sahin B, Ergin M and Guvenc B:
Loss of CD20 antigen expression after rituximab therapy of CD20
positive B cell lymphoma (diffuse large B cell extranodal marginal
zone lymphoma combination): A case report and review of the
literature. Med Oncol. 29:1223–1226. 2012. View Article : Google Scholar : PubMed/NCBI
|
